SCHEMBL376318

SCHEMBL376318

COC1(Cc2ccccc2F)CCC(N2CCNCC2)CC1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 9/20 0.39
SLC6A2 P23975 8/20 0.39
HTR1A P08908 3/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KCNH2 Q12809 3/20 0.38
CYP2D6 P10635 3/20 0.38
HTR6 P50406 1/20 0.38
SLC6A3 Q01959 4/20 0.38
DPP4 P27487 1/20 0.35
LMNA P02545 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
GNAI3 P08754 1/20 0.34
USP2 O75604 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL376616 0.87 LMNA (0.44) SLC6A4SLC6A2HPGDKMT2ASMN1; SMN2
SCHEMBL376343 0.86 ALDH1A1 (0.41) SLC6A4SLC6A2HPGDKMT2ASMN1; SMN2
SCHEMBL376739 0.86 KMT2A (0.39) SLC6A4SLC6A2HPGDKMT2ASMN1; SMN2
SCHEMBL376578 0.83 HPGD (0.46) HPGDKMT2ASMN1; SMN2LMNA
SCHEMBL8111586 0.82 SLC6A2 (0.39) SLC6A4SLC6A2HTR1AKMT2AKCNH2
SCHEMBL13503988 0.78 ALDH1A1 (0.35) SLC6A4SLC6A2HTR1AHPGDKMT2A
SCHEMBL376926 0.78 GPR119 (0.48) KMT2ASMN1; SMN2DPP4
SCHEMBL376372 0.75 MAPT (0.43) SLC6A4KMT2ACYP2D6
SCHEMBL376371 0.75 MAPT (0.43) SLC6A4KMT2ACYP2D6
SCHEMBL13503628 0.75 OPRL1 (0.36) SLC6A4SLC6A2SMN1; SMN2SLC6A3HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765778-B1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2012-01-25 EP disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-7585858-B2 N-sulfonylcarboximidamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-09-08 US disclosed
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters ABBVIE INC. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BAD SLC6A4 3627/4885SLC6A2 4418/4885HTR1A 3138/4885
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters BAX, BCL2, BAD SLC6A4 3627/4885SLC6A2 4418/4885HTR1A 3138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.